The industry is expected to grow at a CAGR of 12.2% from 2025 to 2035
The underlying mechanism includes ER and growth factor-signaling pathways and involves proteins such as phosphorylated mitogen-activated protein kinase, PAKT, BCL2, and angiogenesis and vascular endothelial growth factor (Saggar et al., 2010)
While exenatide provides clinically meaningful glycemic control, its impact on weight loss is relatively modest compared to more recent GLP-1R agents, resulting in less than 3 kg of weight reduction over a 30-week period (DeFronzo et al., 2005
Combinatorial Targeting of XPO1 and FLT3-ITD Exerts Synergistic Anti-Tumor Effects in FLT3-Mutated Acute Myeloid Leukemias
T.ThummelK
This growth is supported by the continued dominance of injectable GLP-1 agonists, which currently account for the majority of revenue, but with a notable shift toward oral formulations as they gain formulary access and physician confidence